Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy
Authors:
- 8 April 2019
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (6) , 973-982
Abstract
Pleomorphic dermal sarcomas (PDS) are sarcomas of the skin with local recurrences in up to 28% of cases, and distant metastases in up to 20%. Although recent evidence provides a strong rational to explore immunotherapeutics in solid tumors, nothing is known about the immune environment of PDS.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB829)
- Else Kröner-Fresenius-Stiftung (EKFS-2014-A06 and 2016_Kolleg)
This publication has 44 references indexed in Scilit:
- Tumor Mutational Burden and Response Rate to PD-1 InhibitionNew England Journal of Medicine, 2017
- Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomasOncotarget, 2017
- Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five casesBritish Journal of Dermatology, 2016
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaNew England Journal of Medicine, 2016
- Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancerOncology Letters, 2016
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 2016
- Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomasOncotarget, 2016
- Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimatedJournal of Cutaneous Pathology, 2015
- Pleomorphic Dermal SarcomaAmerican Journal of Surgical Pathology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012